

Gillian Moore

Associate, New York



PHONE: 212-808-1075
gmoore@desmaraisllp.com

FAX: 212-351-3401

Ms. Moore's practice focuses on intellectual property litigation in life-sciences, medical device, and semiconductor technologies. Her litigation experience includes preparing contentions, drafting motions, and preparing witnesses for trial. She also maintains a pro bono practice, and recently secured a favorable settlement on behalf of an incarcerated individual in a 42 U.S.C. § 1983 case.

During law school, Ms. Moore served as Submissions Editor (2020–2021) and Managing Editor (2021–2022) for *The Virginia Journal of Law and Technology*. Ms. Moore also counseled and prepared patent applications for faculty inventors as a member of the University of Virginia Patent and Licensing Clinic. Prior to starting her legal career, Ms. Moore worked in clinical research at Memorial Sloan Kettering Cancer Center, where she managed Phase I-III clinical trials related to stem cell transplantation and graft versus host disease. Her research has been published in peer-reviewed medical journals and presented at national conferences.

Prior Experience

- Summer Associate, Desmarais LLP, New York, NY, 2021
- Legal Intern, Roivant Sciences, New York, NY 2020
- Clinical Research Associate, Memorial Sloan Kettering Cancer Center (2015-2019)

Publications

- Scientific Articles:
 - Marina Burgos da Silva, et al., *Preservation of fecal microbiome is associated with reduced severity of Graft-versus-Host Disease*, 140 Blood 2385 (2022).
 - Doris M. Ponce, et al., *A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract*, 141 Blood 1389 (2023).
- Abstracts:

EDUCATION

University of Virginia School of Law, J.D., 2022

New York University, M.S.,
Bioinformatics, 2019

Colgate University, A.B., Chemistry
and Philosophy, 2014; *with Honors*

ADMISSIONS

2023, New York

- Doris M Ponce, MD, et al., *Sparing of the Lower Gastrointestinal Tract Microbiota Is Associated with Reduced Acute Graft-Versus-Host Disease*, 134 (Supplement 1) Blood 4538 (2019).
- Kate A Markey, PhDMBBS, et al., *Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease*, 132 (Supplement 1) Blood 359 (2018).
- Doris M. Ponce MD, et al., *A Phase 2 Study of F-652, a Novel Tissue-Targeted Recombinant Human Interleukin-22 (IL-22) Dimer, for Treatment of Newly Diagnosed Acute Gvhd of the Lower GI Tract*, 26 Biology Blood and Marrow Transplantation S51 (2020).
- Doris M. Ponce, MD et al., *Photobiomodulation (PBM) Provides a Prompt and Near-Resolution Response to Advanced Oral Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)*, 25 Biology Blood and Marrow Transplantation S253 (2019).
- Marina Burgos da Silva, et al., *Intestinal dysbiosis predicts lower gastrointestinal tract acute graft-versus-host (aGVHD) disease development*, 204 (1 Supplement) J. Immunology 87.3 (2020).